<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34793746</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1474-547X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>398</Volume>
            <Issue>10315</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
              <Day>27</Day>
            </PubDate>
          </JournalIssue>
          <Title>Lancet (London, England)</Title>
          <ISOAbbreviation>Lancet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial.</ArticleTitle>
        <Pagination>
          <StartPage>1965</StartPage>
          <EndPage>1973</EndPage>
          <MedlinePgn>1965-1973</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(21)02394-1</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0140-6736(21)02394-1</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Intragastric balloons are anatomy-preserving, minimally invasive obesity therapies. Enhanced tolerance and durability could help broaden clinical adoption. We investigated the safety and efficacy of an adjustable intragastric balloon (aIGB) in adults with obesity.</AbstractText>
          <AbstractText Label="METHODS">In this prospective, multicentre, open-label, randomised clinical trial done at seven US sites, adults aged 22-65 years with obesity were randomly assigned (2:1) to aIGB with lifestyle intervention or lifestyle intervention alone (control) for 32 weeks. Balloon volume could be increased to facilitate weight loss or decreased for tolerability. Coprimary endpoints included mean percentage total bodyweight loss and responder rate (≥5% total bodyweight loss) at 32 weeks. We used a multiple imputed intention-to-treat population analysis. This study was registered with ClinicalTrials.gov, NCT02812160.</AbstractText>
          <AbstractText Label="FINDINGS">Between Aug 9, 2016, and Dec 7, 2018, we randomly assigned 288 patients to aIGB (n=187 [65%]) or control (n=101 [35%]) groups. Mean total bodyweight loss at 32 weeks was 15·0% (95% CI 13·9-16·1) in the aIGB group versus 3·3% (2·0-4·6) in the control group (p&lt;0·0001). Clinical response was observed in 171 (92%) patients in the aIGB group. Adjustments to the aIGB occurred in 145 (80%) patients for weight loss plateau or intolerance. Upward volume adjustment facilitated an additional mean 5·2% (4·5-5·8) total bodyweight loss. Downward volume adjustment allowed 21 (75%) patients in the aIGB group to complete the full duration of therapy. Intolerance caused early removal of the device in 31 (17%) patients. No micronutrient deficiencies were observed in the aIGB cohort. Device-related serious adverse events were observed in seven (4%) patients, without any deaths.</AbstractText>
          <AbstractText Label="INTERPRETATION">When aIGB was combined with lifestyle modification, significant weight loss was achieved and maintained for 6 months following removal. Balloon volume adjustability permitted individualised therapy, maximising weight loss and tolerance.</AbstractText>
          <AbstractText Label="FUNDING">Spatz Medical.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Abu Dayyeh</LastName>
            <ForeName>Barham K</ForeName>
            <Initials>BK</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Electronic address: abudayyeh.barham@mayo.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maselli</LastName>
            <ForeName>Daniel B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rapaka</LastName>
            <ForeName>Babusai</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lavin</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Surgical Associates of Louisiana, Metairie, LA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Noar</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Endoscopic MicroSurgery Associates, Towson, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hussan</LastName>
            <ForeName>Hisham</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Hepatology and Nutrition, Ohio State University Wexner Medical Center, Columbus, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chapman</LastName>
            <ForeName>Christopher G</ForeName>
            <Initials>CG</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine, Chicago, IL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Popov</LastName>
            <ForeName>Violeta</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, NYU Langone Health, VA Medical Center, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jirapinyo</LastName>
            <ForeName>Pichamol</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Acosta</LastName>
            <ForeName>Andres</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vargas</LastName>
            <ForeName>Eric J</ForeName>
            <Initials>EJ</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Storm</LastName>
            <ForeName>Andrew C</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bazerbachi</LastName>
            <ForeName>Fateh</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>CentraCare, Interventional Endoscopy Program, St Cloud Hospital, St Cloud, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ryou</LastName>
            <ForeName>Marvin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>French</LastName>
            <ForeName>Matthew</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Surgical Associates of Louisiana, Metairie, LA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Noria</LastName>
            <ForeName>Sabrena</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Hepatology and Nutrition, Ohio State University Wexner Medical Center, Columbus, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Molina</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Biostatistics and Clinical Data Management, Technical Resources International, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thompson</LastName>
            <ForeName>Christopher C</ForeName>
            <Initials>CC</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02812160</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Lancet</MedlineTA>
        <NlmUniqueID>2985213R</NlmUniqueID>
        <ISSNLinking>0140-6736</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Lancet. 2021 Nov 27;398(10315):1940-1941</RefSource>
          <PMID Version="1">34793744</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):6</RefSource>
          <PMID Version="1">34815534</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Lancet. 2021 Nov 27;398(10315):1964</RefSource>
          <PMID Version="1">34838178</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020878" MajorTopicYN="N">Device Removal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015905" MajorTopicYN="Y">Gastric Balloon</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005773" MajorTopicYN="N">Gastroscopy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008019" MajorTopicYN="N">Life Style</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015431" MajorTopicYN="Y">Weight Loss</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Declaration of interests BKA reports consultant roles with Endogenex, Endo-TAGSS, Metamodix, and BFKW; consultant and grant or research support from USGI, Cairn Diagnostics, Aspire Bariatrics, Boston Scientific; speaker roles with Olympus, Johnson and Johnson; speaker and grant or research support from Medtronic, Endogastric solutions; and research support from Apollo Endosurgery and Spatz Medical. CGC reports consultant roles with Olympus; consultant roles and payment or honoraria from Apollo Endosurgery and Boston Scientific; payment or honoraria from AbbVie; participation in a data safety monitoring board and consultant roles with Erbe, BFKW, and Nitinotes Surgical. VP reports consultancy fees from Obalon Therapeutics. PJ reports grants from Boston Scientific; patent licensed to Endosim; consulting fees from Endogastric solutions and Erbe; support for meetings from USGI medical; consulting fees and research support from Gastrointestinal Dynamics; and research support from Apollo Endosurgery and Fractyl. AA reports grants from the National Institutes of Health—National Institute of Diabetes and Digestive and Kidney Diseases, American Neurogastroenterology and Motility Society, Mayo Clinic Center for Individualized Medicine; stockholder of Gila Therapeutics and Phenomix Sciences; personal fees from Rhythm Pharmaceuticals, General Mills, Gila Therapeutics; and patent PCT/US62/589915 licensed to Phenomix Sciences. ACS reports institutional research grants from Boston Scientific, Enterasense, Endogenex; consulting fees from Olympus; consulting fees and research grants from Endo-TAGSS, and Apollo Endosurgery; participation in data safety monitoring board with Gastrointestinal Dynamics and Erbe. MR reports consultant roles with Boston Scientific, Fujifilm, Medtronic, Enterasense, and Gastrointestinal Windows; and consultant and research support from Cook Medical. DM reports financial support from Spatz Medical for statistical analysis for this trial. CCT reports institutional research grants from Aspire Bariatrics, Erbe, and Spatz Medical; royalties from Endosim and Enterasense; consulting fees and research grants from Apollo Endosurgery, Boston Scientific, Covidien/Medtronic, Fractyl, Fujifilm, Gastrointestinal Dynamics, Lumendi, Olympus, and USGI; payment or honoraria from Boston Scientific and Olympus; patents licensed to Boston Scientific, Gastrointestinal Windows, Enterasense, EnVision Endoscopy, and Endosim; participation in data safety monitoring board with Gastrointestinal Dynamics, Fractyl, and USGI; leadership or fiduciary role in other board with Enterasense, EnVision Endoscopy, Gastrointestinal Windows, American Society for Gastrointestinal Endoscopy governing board, and BlueFlame Healthcare Venture Fund; stockholder in Gastrointestinal Windows, Enterasense, EnVision Endoscopy; and has received equipment on loan from Fujifilm, Olympus, and Boston Scientific. All other authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>18</Day>
          <Hour>20</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34793746</ArticleId>
        <ArticleId IdType="doi">10.1016/S0140-6736(21)02394-1</ArticleId>
        <ArticleId IdType="pii">S0140-6736(21)02394-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
